Meeting Report

The 4 T’s of ITP: Tailoring Therapies to Treat Thrombocytopenia

David Hughes, PharmD, BCOP

From Boston University School of Medicine, Boston, Massachusetts

Presenter’s disclosure of conflicts of interest is found at the end of this article.


J Adv Pract Oncol 2022;13(3):337–340 | https://doi.org/10.6004/jadpro.2022.13.3.32 | © 2022 Harborside™


  

ABSTRACT

Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David Hughes, PharmD, BCOP, reviewed the background and pathophysiology of ITP and clinical practice guidelines with an emphasis on patient preference when selecting first and subsequent lines of therapies in the chronic ITP setting.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.